Jeff Goldberg has served in interim operating executive roles and board director capacities in partnership with AHP on its investments in Promises Behavioral Health and Advantia Health. Jeff’s past board chair roles include 21st Century Oncology (comprehensive cancer treatment), MModal (clinical documentation software and services), Surgical Specialties Corporation (fka Angiotech Pharmaceuticals) and Physiotherapy Associates.

Prior to his more recent board roles, Jeff worked with the late Al Mann, founder of Pacesetter, MiniMed, Second Sight, and Advanced Bionics. Jeff’s work with Al Mann was as president of IncuMed – the technology incubator for Al’s development-level companies (tinnitus, diabetes, advanced technologies supporting defense and intelligence agencies, etc.). Before that, he was SVP & General Counsel for Advanced Bionics (AB), which designed and sold spinal cord stimulators and cochlear implants, eventually acquired by Boston Scientific.

Prior to that, Jeff served as CFO of a specialty hospital, as operational leader for an advanced battery technology business, on an assembly line for consumer electronics in China (briefly), as lead ’34 Act counsel for Occidental Petroleum Corporation, and as an M&A lawyer.

Jeff holds an A.B. in Philosophy from Harvard University and a J.D. from the UCLA School of Law.